The board of directors of Simcere Pharmaceutical Group Limited announce that, on June 17, 2021, the trial application for a multicenter and open-label Phase Ib/II clinical study for evaluation on treatment of advanced solid tumors with Envafolimab in combination with Lenvatinib as undertaken by the Company in collaboration with 3D Medicines (Beijing) Co. Ltd. ("3D Medicines (Beijing)") and Jiangsu Alphamab Biopharmaceuticals Co. Ltd. ("Jiangsu Alphamab") has obtained the approval issued by the National Medical Products Administration, PRC. According to the approval, the Company proposes to use Envafolimab in combination with Lenvatinib for treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) who were refractory to prior PD-(L)1 inhibitor treatment and patients with locally advanced or metastatic RCC who had never accepted systemic treatment for advanced diseases. On March 30, 2020, the Company entered into a tripartite cooperation agreement in relation to Envafolimab with 3D Medicines (Beijing) and Jiangsu Alphamab and also entered into a separate marketing and promotion agreement with 3D Medicines (Beijing). The abovementioned agreements provide the company with the exclusive right to promote Envafolimab for oncology treatment indications in Mainland China.